ClinicalTrials.gg
RecruitingNCT06582628TEAM PCUpdated Oct 5, 2026

Talazoparib Plus Enzalutamide After Progression to Prior ARPi in Metastatic Prostate Cancer

A Phase 2 interventional study of Enzalutamide capsule and Enzalutamide capsule and Talazoparib capsule in Metastatic Prostate Cancer, sponsored by Fundacion Oncosur. Recruiting at 19 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Fundacion Oncosur · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.
Updated Oct 5, 2026First site in FranceSite recruiting status changed+8 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
78
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 125 studies testing enzalutamide in Prostatic Neoplasms — 17 open to participants now, 38 under way, 9 of them phase 3. enzalutamide · Prostatic Neoplasms.

Planned enrollment
45th of 125
78 · median 52
Started
2024
with 4 others
Phase 2
65 of 125
8 open now
Primary completion
2027-12
later than 31 of 37 live
Registered
119th of 125
by date

Among the 125 studies testing enzalutamide in Prostatic Neoplasms, this one is the 45th largest by planned enrollment, is one of 5 that started in 2024, is one of 65 in phase 2, reaches primary completion later than 31 of the 37 other live ones, and was the 119th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

17 of the 125 studies testing enzalutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About enzalutamide

enzalutamide: first FDA approval 2012 (XTANDI), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing enzalutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this clinical trial is to determine the anti-tumor activity of talazoparib plus enzalutamide as first line treatment for metastatic castration resistant prostate cancer (mCRPC) in participants whose disease has progressed on Androgen Receptor Pathway Inhibitor (ARPI).

The main questions it aims to answer are:

  • Does talazoparib plus enzalutamide improve efficacy in metastatic castration resistant prostate cancer (mCRPC) compared to enzalutamide alone?
  • What is the time to disease progression [radiographic, Prostate Specific Antigen (PSA), clinical] in participants treated with talazoparib plus enzalutamide after progression on abiraterone?
  • What medical problems do participants have when receiving talazoparib plus enzalutamide?

Researchers will compare the combination of talazoparib and enzalutamide as a first-line treatment for mCRPC to see if the combination improves the PSA response rate and delays progression compared to enzalutamide alone. The safety and tolerability of the combination (talazoparib and enzalutamide) will also be studied

Read the detailed description

This is a multicenter, open-label, randomized, phase II trial to evaluate the efficacy of the combination of talazoparib plus enzalutamide versus enzalutamide as first line treatment for metastatic castration resistant prostate cancer (mCRPC) in participants whose disease has progressed to abiraterone or other androgen receptor inhibitors (ARi) based treatment for metastatic hormone sensitive prostate cancer (mHSPC). Participants who meet the eligibility criteria will be randomized 2:1 to the experimental arm (enzalutamide and talazoparib) or control arm (enzalutamide) and will receive treatment until disease progression, unacceptable toxicity, death or discontinuation from the study treatment for any other reason.

The experimental arm will be evaluated as 2 separate arms, post-AA and post-ARi, each with a single-stage phase II trial design. The control arm will not be directly compared to the experimental arm but will be used to explore biomarker differences in outcome measures between the experimental and control arm and confirm the statistical assumptions for the response rate under the null hypothesis.

Prostate cancer is the second most common malignancy in men worldwide with an estimated annual global incidence of 1.3 million and over 375,000 deaths. Aggressive variant prostate cancer is a clinically defined subset of metastatic castration resistant prostate cancers (mCRPC) characterized by the absence of response to androgen receptor (AR) targeted agents and neuroendocrine features. The treatments that are currently available are not effective, representing an unmet clinical need. The combination of talazoparib, a potent selective PARP inhibitor (PARPi) and enzalutamide (androgen receptor signaling inhibitor; ARPi) demonstrated in the TALAPRO-2 study improved efficacy in metastatic castration resistant prostate cancer (mCRPC) participants with and without DNA damage response (DDR) gene alterations as first line treatment (1L) compared to enzalutamide alone.

Estimated duration of the study: 48 months. Accrual is expected to be completed in 30 months. Median treatment duration has been estimated in 10 months. After completion of (or discontinuation from) treatment, participants will be followed up for survival until end of study (EoS) that will occur at 18 months after the enrollment of the last patient included in the trial, unless premature termination of the study.

It is hypothesized that after progression to abiraterone, the addition of talazoparib to enzalutamide as 1L for mCRPC will result in improved PSA response rate and delayed progression compared to enzalutamide alone.

03

Conditions studied

  • Metastatic Prostate Cancer

Keywords

  • Prostatic Diseases
  • Prostatic Cancer
  • metastatic castration resistant prostate cancer (mCRPC)
  • prostate adenocarcinoma
  • metastatic hormone-sensitive prostate cancer
  • Poly (ADP-ribose) Polymerases (PARP)
  • Prostate Specific Antigen
  • Abiraterone
04

Who can participate

The criteria were revised on the registry on Oct 5, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male age 18 or older.
  2. Histological diagnosis of prostate adenocarcinoma without neuroendocrine differentiation or small cell features.
  3. Willing and able to provide written to participate in the study. Written consent must be given before registration, according to International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) / Good clinical practice (GCP), and national/local regulations.
  4. (ECOG) performance status 0 or 1.
  5. Willing to provide tumor during the study. Note: At study entry, the pre-treatment new tumor biopsy (fresh-frozen and Formalin-fixed and paraffin-embedded (FFPE) material) could be replaced by an archived tumor biopsy upon agreement from the study chief investigator if such biopsy has been taken after progression to castration resistance and has both archived fresh-frozen material and a FFPE block with a minimum tumor content over 30 percent. Still the patient must be amenable and willing to undergo a new mandatory post-treatment biopsy.
  6. Willing to provide blood samples for biomarker analysis.
  7. Willing to give consent to sequencing of DNA damage repair (DDR) genes for analysis of the prevalence of somatic and germline aberrations in DNA damage repair genes.
  8. Metastatic (M1) prostate cancer documented by bone scan, or soft tissue disease documented by computed tomography (CT), or magnetic resonance imaging (MRI).
  9. Asymptomatic or minimally symptomatic prostate cancer at screening.
  10. Estimated of greater than or equal to 6 months from screening.
  11. Ongoing androgen deprivation therapy (ADT) with a gonadotropin-releasing hormone (GnRH) agonist or antagonist for participants who have not undergone bilateral orchiectomy must be in place before screening and must continue throughout the study.

12 .Disease progression after at least 12 weeks of treatment with a prior androgen-receptor signalling inhibitor (ARPi), including abiraterone acetate or a direct AR inhibitor, such as enzalutamide, apalutamide, or darolutamide, for metastatic hormone-sensitive prostate cancer. Note: Patients who previously received Enzalutamide can be recruited but up to a maximum of 6. Those patients will be included directly into the experimental arm. Progression is defined as:

a. PSA rise of greater than or equal to 25 percent and an absolute increase of greater than or equal to 2 ng/mL above nadir (or baseline for participants with no PSA decline), confirmed by a second PSA value at least 3 weeks later.

and / or b. Limited radiographic progression: maximum of 2 new bone metastases, no new soft tissue metastasis and less than 50 percent increase in the size of measurable soft tissue lesions.

13. Participants who have received prior docetaxel must meet the following criteria:

a. Received a maximum of 6 cycles of docetaxel for mHSPC and b. Received the last dose of docetaxel equal or higher than 6 months prior to randomization.

14. Participants who have received prior Lu177-PSMA must meet the following criteria:

a. Received a maximum of 6 cycles of docetaxel for mHSPC. b. Received the last dose of Lu177-PSMA equal or higher than 6 months prior to randomization 15. Adequate organ function within 28 days before the first study treatment on Day 1, defined by the following:

  1. greater than or equal to 10 g/dL, no blood transfusions within 14 days before obtaining the haematology laboratory tests at screening,
  2. greater than or equal to 100,000/μL no platelets transfusions within 14 days before obtaining the haematology laboratory tests at screening,
  3. Neutrophils greater than or equal to 1500/μL, no growth factors given within 14 days before obtaining the haematology laboratory tests at screening,
  4. Serum creatinine less than1.5X or calculated greater than or equal to 50 mL/min
  5. Albumin greater than 3 g/dL,
  6. or ALT less than 2.5 × ULN (less than 5 × ULN if liver function abnormalities are due to hepatic metastasis).
  7. Total serum less than 1.5 × ULN (less than 3 × ULN for participants with documented Gilbert syndrome or for whom indirect bilirubin concentrations suggest an extrahepatic source of elevation). 16. Ability to swallow study medication tablets and comply with study requirements.

    17. Agrees to use a condom and another effective method of if he is having sex with a woman of or agrees to use a condom if he is having sex with a woman who is pregnant, starting contraception at screening and continue throughout the study period and for 3 months after the final treatment administration, (during the treatment period and for at least 90 days after last dose of enzalutamide or at least 120 days after las dose of talazoparib, whichever occurs later) unless the patient is unable to maintain intercourse due to the androgen deprivation.

    18. Subjects must not donate sperm starting at screening and throughout the study period and for 3 months after the final abiraterone acetate administration.

    19. Subject agrees not to participate in another interventional study while with experimental medical products or anticancer drugs not approved in this setting on treatment in this study. Exceptions could be allowed for protocols investigating the survival or quality of life impact of common routine or conventional drugs (i.e. acetylsalicylic acid, statins, oral antidiabetic drugs) as long as they do not intefere with the study treatment and the evaluation of the main study arms.

    20. Willing and able to comply with all scheduled visits, treatment plan, laboratory tests and other study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Prior ARPi treatment for less than 12 weeks or disease progression (either PSA or radiographic progression) within 6 months of starting abiraterone or ARi.
  2. Known or suspected or active .
  3. Symptomatic or impending spinal cord compression or cauda equina syndrome.
  4. Use of opiate analgesia for pain from prostate cancer with average Brief pain inventory (BPI) questionnaire score higher than or equal to 6 and/or uncontrolled prostate cancer-related pain requiring increasing doses of opiates within 4 weeks prior to randomization
  5. Prior treatment with more than one ARPi. This will include abiraterone, enzalutamide, apalutamide, or darolutamide, which are treatments with demonstrated PFS and/or OS benefit in mHPSC, as well as any other novel AR or androgen synthesis directed therapy (with the exception on LHRH/GnRH analogues and/or antagonists). Note: Patients who started on one ARPi and switched to another due to toxicity will only be eligible after prior discussion with the study chair, provided that they were on the first ARPi (other than enzalutamide) for a very limited period of time and can document that they were responding - without PSA rise or worsening symptoms - at the moment they were switched to the second ARPi. Inclusion of such cases will require written notification and approval from the study chair or co-chair.
  6. Therapeutic radiation therapy within, 14 days (7 days for limited-field palliative radiotherapy) prior to study enrolment, or participants who have not recovered from radiotherapy-related toxicities to grade less than or equal to 1 according to v.5.0.
  7. Major surgery within 4 weeks prior to randomization or participants who have not recovered from the side effects of any major surgery.
  8. Administration of an therapeutic or invasive surgical procedure (not including surgical castration) within 30 days of Cycle 1 Day 1 or currently enrolled in an investigational study.
  9. History of seizure or any condition that may predispose to seizure (i.e., prior significant brain trauma, brain vascular malformation, etc) or subjects that have had an unexplained loss of consciousness or within 1 year previous to scheduled day 1 of treatment.
  10. Congenital long syndrome or at screening with QT interval corrected using Fridericia's formula (QTcF) greater than 500 milliseconds.
  11. Participants with cardiovascular disease including but not limited to any of the following:

    1. Stroke, transient ischemic attack, unstable angina pectoris or documented myocardial infarction within 12 months prior to study entry.
    2. Symptomatic pericarditis or clinically significant pericardial effusion or myocarditis
    3. Documented congestive heart failure ( Class, NYHA functional classification III-IV)
    4. Uncontrolled, persistent hypertension defined as systolic blood pressure greater than 170mmHg or diastolic blood pressure greater than100mmHg. Subjects with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive treatment
  12. Participants with any of the following cardiac conduction abnormalities:

    1. Ventricular arrhythmias except for benign premature ventricular contractions
    2. Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled with medication.
    3. Conduction abnormality requiring a pacemaker.
    4. Other cardiac arrhythmia not controlled with medication.
  13. Any clinically significant gastrointestinal disorder affecting absorption (i.e., extensive small bowel resection, active inflammatory bowel disease).
  14. Active or symptomatic viral hepatitis or chronic liver disease.
  15. Known/possible , allergies to enzalutamide, talazoparib or any of capsule .
  16. Other except:

    1. Carcinoma in situ or non-melanoma skin cancer.
    2. A cancer diagnosed and treated greater than or equal to 5 years before randomization with no subsequent evidence of recurrence.
  17. Any condition or situation which, in the opinion of the investigator, would put the subject at risk, may confound study results, or interfere with the subject's participation in this study.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
78 participants (estimated)

Study arms

  • Active comparator
    Control

    Enzalutamide 160 mg orally daily continuously in 28-day cycles.

    Drug: Enzalutamide capsule

  • Experimental
    Enzalutamide and Talazoparib. Post-AA/ARi according to prior treatment.

    Enzalutamide 160 mg and Talazoparib 0.5 mg both orally daily and continuously in 28-day cycles. Note: Patients who previously received Enzalutamide will be included directly into the investigational arm. (Up to a maximum of 6).

    Drug: Enzalutamide capsule and Talazoparib capsule

Interventions

06

What researchers measure

Primary outcomes

  1. PSA response (PSA50)

    Percentage of participants with a PSA decline greater than or equal to 50 percent from baseline confirmed by a consecutive PSA value (taken at least 3 weeks apart), prior to PSA progression

    Time frame: within the first 16 weeks

  2. Objective response rate (ORR)

    Defined as the best overall radiographic response (partial or complete) during the first 16 weeks on follow up as per investigator assessment of soft tissue/visceral disease per RECIST 1.1 in subjects who have a measurable tumour and/or Prostate Cancer Working Group 3 (PCWG3) criteria for bone metastases

    Time frame: during the first 16 weeks

Secondary outcomes

  1. Radiographic Progression Free Survival (rPFS)

    Time from randomization to first objective evidence of radiographic progression, based on RECIST 1.1 for soft tissue/visceral disease and Prostate Cancer Clinical Trials Working Group 3 (PCWG3) guidelines for bone metastases, or death, whichever occurs first.

    Time frame: Through study completion, an average of 2 years

  2. Time to PSA Progression (TTPP)

    Time from randomization to PSA progression defined as PSA greater than or equal to 25 percent and greater than or equal to 2ng/mL from nadir (or baseline for participants with no PSA decline), confirmed by a second value obtained 3 or more weeks apart as per PCWG3 guidelines.

    Time frame: Through study completion, an average of 2 years

  3. Time to unequivocal clinical progression (TTCP)

    Time from randomization to clinical worsening of prostate cancer related symptoms, as new onset cancer pain requiring chronic administration of opiate analgesia, deterioration from prostate cancer of Eastern Cooperative Oncology Group (ECOG) performance status score to 3 or higher, time to first skeletal-related event (the time from randomization to first incidence of radiotherapy to the bone or bone surgery, pathological bone fracture, spinal cord compression, or change of antineoplastic therapy to treat bone pain); or initiation of subsequent lines of active treatment including cytotoxic chemotherapy or radiation therapy or surgical intervention due to complications or symptoms related to disease progression.

    Time frame: Through study completion, an average of 2 years

  4. Progression Free Survival (PFS)

    Time from randomization to PSA progression, unequivocal clinical progression or radiographic progression, whichever occurs first.

    Time frame: Through study completion, an average of 2 years

  5. Incidence of adverse events (AEs)

    Total, grouped by grades and AEs category, related and unrelated with the trial treatment. The AEs Defined as incidence of prespecified AEs as per National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) v.5.0, change from baseline in targeted vital signs and change from baseline in targeted clinical laboratory test results.

    Time frame: Through study completion, an average of 2 years

  6. Incidence of serious adverse events (SAEs)

    Number of Serious Adverse Events, related and unrelated. SAEs leading to treatment discontinuation.

    Time frame: Through study completion, an average of 2 years

  7. Drug compliance

    Percentage of dose taken for each treatment drug, dose reductions, dose discontinuation (temporary or permanent)

    Time frame: Through study completion, an average of 2 years

Other outcomes

  1. Assessment of PSA response rate

    In participants with and without germline and/or somatic DDR alterations.

    Time frame: Through study completion, an average of 2 years

  2. Assessment of ORR

    In participants with and without germline and/or somatic DDR alterations

    Time frame: Through study completion, an average of 2 years

  3. Assessment of rPFS

    In participants with and without germline and/or somatic DDR alterations

    Time frame: Through study completion, an average of 2 years

  4. Assessment of TTPP

    In participants with and without germline and/or somatic DDR alterations.

    Time frame: Through study completion, an average of 2 years

  5. Assessment of TTCP

    In participants with and without germline and/or somatic DDR alterations.

    Time frame: Through study completion, an average of 2 years

  6. Changes in expression levels of AR in tissue

    Changes from tissue samples, studying the correlation of these changes with clinical activity

    Time frame: Through study completion, an average of 2 years

  7. Changes in expression levels of AR in plasma

    Changes from plasma samples, studying the correlation of these changes with clinical activity

    Time frame: Through study completion, an average of 2 years

  8. Changes in expression of AR-related genes in tissue

    Changes from tissue samples, studying the correlation of these changes with clinical activity

    Time frame: Through study completion, an average of 2 years

  9. Changes in expression of AR-related genes in plasma

    Changes from plasma samples, studying the correlation of these changes with clinical activity

    Time frame: Through study completion, an average of 2 years

  10. Changes in open chromatin regions in tissue

    Changes from tissue samples, studying the correlation of these changes with clinical activity

    Time frame: Through study completion, an average of 2 years

  11. Changes in open chromatin regions in plasma

    Changes from plasma samples, studying the correlation of these changes with clinical activity

    Time frame: Through study completion, an average of 2 years

  12. Survival signaling in tissue

    Changes from tissue samples, studying the correlation of these changes with clinical activity

    Time frame: Through study completion, an average of 2 years

  13. Survival signaling in plasma

    Changes from plasma samples, studying the correlation of these changes with clinical activity

    Time frame: Through study completion, an average of 2 years

  14. DNA-damage in tissue

    Changes from tissue samples, studying the correlation of these changes with clinical activity

    Time frame: Through study completion, an average of 2 years

  15. DNA-damage in plasma

    Changes from plasma samples, studying the correlation of these changes with clinical activity

    Time frame: Through study completion, an average of 2 years

  16. Deficient/proficient DNA-repair in tissue

    Changes from tissue samples, studying the correlation of these changes with clinical activity

    Time frame: Through study completion, an average of 2 years

  17. Deficient/proficient DNA-repair in plasma

    Changes from plasma samples, studying the correlation of these changes with clinical activity

    Time frame: Through study completion, an average of 2 years

  18. Other biomarkers in tissue

    Changes from tissue samples, studying the correlation of these changes with clinical activity

    Time frame: Through study completion, an average of 2 years

  19. Other biomarkers in plasma

    Changes from plasma samples, studying the correlation of these changes with clinical activity

    Time frame: Through study completion, an average of 2 years

07

Study locations

15 of 19 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Dec 2027, 41 months after the start.

Of 613 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's planned 41 months is below that.

Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: primary completion Jan 2026 → Dec 2027 and completion Oct 2027 → Feb 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2024
First posted
Sep 3, 2024
StartActual
Jul 5, 2024
Primary completionEst.
Dec 31, 2027was Jan 2026
CompletionEst.
Feb 28, 2029was Oct 2027
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
14 sites added, 7 sites removed — first site in France. Hospital Universitario de Jerez de la Frontera is now Withdrawn
Show 14 added (8 Spain, 6 France)
  • Institut Bergonié · Bordeaux, France
  • Hôpital Universitaire de Brest · Brest, France
  • Centre Oscar Lambret · Lille, France
  • Hôpital Saint Joseph · Paris, France
  • Hôpitaux Universitaire de Strasbourg · Strasbourg, France
  • Institut Gustave Roussy · Villejuif, France
  • Hospital del Mar · Barcelona, Spain
  • Hospital Clínico y Provincial de Barcelona · Barcelona, Spain
  • Hospital Clínico San Carlos · Madrid, Spain
  • Hospital 12 de Octubre · Madrid, Spain
  • Hospital Universitario La Paz · Madrid, Spain
  • Hospital Universitario Virgen de la Victoria · Málaga, Spain
  • Hospital Universitario Miguel Servet · Zaragoza, Spain
  • Hospital Fundación Jiménez Díaz · Madrid, Spain
Show 7 removed
  • Hospital Universitario Del Mar. · Barcelona, Spain
  • Hospital Clínico y Provincial de Barcelona · Barcelona, Spain
  • Hospital Clínico San Carlos · Madrid, Spain
  • Hospital 12 de Octubre · Madrid, Spain
  • Hospital Universitario La Paz · Madrid, Spain
  • Hospital Universitario Virgen de la Victoria · Málaga, Spain
  • Hospital Universitario Miguel Servet · Zaragoza, Spain
Oct 5, 2026
Primary completion
Jan 31, 2026→Dec 31, 2027
Oct 5, 2026
Study completion
Oct 31, 2027→Feb 28, 2029
Oct 5, 2026
Eligibility
8 inclusion criteria edited, 1 added, 1 removed; 5 exclusion criteria edited, 2 added, 3 removed
What changed in the criteria
Inclusion criteria
  • EditedWilling to provide tumor biopsies during the study. Note: At study entry, the pre-treatment freshnew tumor biopsy (fresh-frozen and Formalin-fixed and paraffin-embedded (FFPE) material) could be replaced by an archived tumor biopsy upon agreement from the study chief investigator if such biopsy has been taken after progression to metastatic castration resistance and has both archived fresh-frozen material and a Formalin-fixed and paraffin-embedded (FFPE) block with a minimum tumor content more less than30over 30 percent. Still the patient must be amenable and willing to undergo a new mandatory post-treatment biopsy.
  • ChangedBefore 12 .Disease progression after at least 12 weeks of treatment with abiraterone for metastatic hormone-sensitive prostate cancer. Progression is defined as:Now 12 .Disease progression after at least 12 weeks of treatment with a prior androgen-receptor signalling inhibitor (ARPi), including abiraterone acetate or a direct AR inhibitor, such as enzalutamide, apalutamide, or darolutamide, for metastatic hormone-sensitive prostate cancer. Note: Patients who previously received Enzalutamide can be recruited but up to a maximum of 6. Those patients will be included directly into the experimental arm. Progression is defined as:
  • Editedand / or b. Limited radiographic progression: maximum of 2 new bone metastases, no new soft tissue metastasis and less than50percentincreasethan 50 percent increase in the size of measurable soft tissue lesions.
  • EditedReceived a maximum of 6 cycles of docetaxel for mHSPC. and b. Received the last dose of docetaxel equal or higher than 6 months prior to randomization.
  • Added14. Participants who have received prior Lu177-PSMA must meet the following criteria:
  • EditedReceived a maximum of 6 cycles of docetaxel for mHSPC. b. Received the last dose of Lu177-PSMA equal or higher than 6 months prior to randomization 15. Adequate organ function within 28 days before the first study treatment on Day 1, defined by the following:
  • EditedTotal serum bilirubin less than 1.5 × ULN (less than 3 × ULN for participants with documented Gilbert syndrome or for whom indirect bilirubin concentrations suggest an extrahepatic source of elevation). 16. Ability to swallow study medication tablets and comply with study requirements.
  • RemovedAbility to swallow study medication tablets and comply with study requirements.
  • Edited17. Agrees to use a condom and another effective method of birth control if he is having sex with a woman of childbearing potential or agrees to use a condom if he is having sex with a woman who is pregnant, starting contraception at screening and continue throughout the study period and for 3 months after the final treatment administration, (during the treatment period and for at least 90 days after last dose of enzalutamide or at least 120 days after las dose of talazoparib, whichever occurs later) unless the patient is unable to maintain intercourse due to the androgen deprivation.
  • ChangedBefore Subject agrees not to participate in another interventional study while on treatment.Now 19. Subject agrees not to participate in another interventional study while with experimental medical products or anticancer drugs not approved in this setting on treatment in this study. Exceptions could be allowed for protocols investigating the survival or quality of life impact of common routine or conventional drugs (i.e. acetylsalicylic acid, statins, oral antidiabetic drugs) as long as they do not intefere with the study treatment and the evaluation of the main study arms.
Exclusion criteria
  • EditedPrior abirateroneARPi treatment for less than 12 weeks or disease progression (either PSA or radiographic progression) within 6 months of starting abiraterone or ARi.
  • RemovedDisease progression less than 6 months after the last administration of docetaxel for mHSPC.
  • RemovedA finding of superscan in a bone scan at screening. Superscan is defined as a bone scan which demonstrates markedly increased skeletal radioisotope uptake relative to soft tissues in association with absent or faint renal activity (absent kidney sign).
  • EditedUse of opiate analgesia for pain from prostate cancer with average Brief pain inventory (BPI) questionnaire score higher than or equal to 6 and/or uncontrolled prostate cancer-related pain requiring increasing doses of opiates within 4 weeks prior to randomization
  • RemovedPrior treatment with an AR-targeted therapy (enzalutamide, apalutamide, darolutamide, ketoconazole) other than abiraterone for mHSPC; chemotherapy other than 6 cycles of docetaxel for mHSPC, immunotherapy or radiopharmaceuticals.
  • AddedPrior treatment with more than one ARPi. This will include abiraterone, enzalutamide, apalutamide, or darolutamide, which are treatments with demonstrated PFS and/or OS benefit in mHPSC, as well as any other novel AR or androgen synthesis directed therapy (with the exception on LHRH/GnRH analogues and/or antagonists). Note: Patients who started on one ARPi and switched to another due to toxicity will only be eligible after prior discussion with the study chair, provided that they were on the first ARPi (other than enzalutamide) for a very limited period of time and can document that they were responding - without PSA rise or worsening symptoms - at the moment they were switched to the second ARPi. Inclusion of such cases will require written notification and approval from the study chair or co-chair.
  • EditedarticipantsParticipants with clinically significant cardiovascular disease including but not limited to any of the following:
  • EditedUncontrolled, persistent hypertension defined as systolic blood pressure lessgreater than 170mmHg or diastolic blood pressure lessgreater than100mmHg. Subjects with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive treatment
  • EditedParticipants with any of the following cardiac conduction abnormalities: Ventricular arrhythmias except for benign premature ventricular contractions
  • AddedVentricular arrhythmias except for benign premature ventricular contractions
Oct 5, 2026
Interventions
Arm changed Enzalutamide and Talazoparib→Enzalutamide and Talazoparib. Post-AA/ARi according to prior treatment.
Oct 5, 2026
Contact
Study contact's phone or email changed: •••3615→•••8227. See the current contact
Oct 5, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Institut Català d'Oncologia (ICO) · Badalona, SpainContact person changed (no phone or email listed)
  • Hospital Universitario de Jerez de la Frontera · Cadiz, SpainContact removed (no phone or email listed)
Oct 5, 2026
Title
Talazoparib Plus Enzalutamide After Progression to AbirateronePrior ARPi in Metastatic Prostate Cancer: (TEAM PC)
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    14 sites added, 7 sites removed — first site in France. Hospital Universitario de Jerez de la Frontera is now Withdrawn
    Show 14 added (8 Spain, 6 France)
    • Institut Bergonié · Bordeaux, France
    • Hôpital Universitaire de Brest · Brest, France
    • Centre Oscar Lambret · Lille, France
    • Hôpital Saint Joseph · Paris, France
    • Hôpitaux Universitaire de Strasbourg · Strasbourg, France
    • Institut Gustave Roussy · Villejuif, France
    • Hospital del Mar · Barcelona, Spain
    • Hospital Clínico y Provincial de Barcelona · Barcelona, Spain
    • Hospital Clínico San Carlos · Madrid, Spain
    • Hospital 12 de Octubre · Madrid, Spain
    • Hospital Universitario La Paz · Madrid, Spain
    • Hospital Universitario Virgen de la Victoria · Málaga, Spain
    • Hospital Universitario Miguel Servet · Zaragoza, Spain
    • Hospital Fundación Jiménez Díaz · Madrid, Spain
    Show 7 removed
    • Hospital Universitario Del Mar. · Barcelona, Spain
    • Hospital Clínico y Provincial de Barcelona · Barcelona, Spain
    • Hospital Clínico San Carlos · Madrid, Spain
    • Hospital 12 de Octubre · Madrid, Spain
    • Hospital Universitario La Paz · Madrid, Spain
    • Hospital Universitario Virgen de la Victoria · Málaga, Spain
    • Hospital Universitario Miguel Servet · Zaragoza, Spain
    Primary completion Jan 31, 2026→Dec 31, 2027
    Study completion Oct 31, 2027→Feb 28, 2029
    Eligibility 8 inclusion criteria edited, 1 added, 1 removed; 5 exclusion criteria edited, 2 added, 3 removed
    What changed in the criteria
    Inclusion criteria
    • EditedWilling to provide tumor biopsies during the study. Note: At study entry, the pre-treatment freshnew tumor biopsy (fresh-frozen and Formalin-fixed and paraffin-embedded (FFPE) material) could be replaced by an archived tumor biopsy upon agreement from the study chief investigator if such biopsy has been taken after progression to metastatic castration resistance and has both archived fresh-frozen material and a Formalin-fixed and paraffin-embedded (FFPE) block with a minimum tumor content more less than30over 30 percent. Still the patient must be amenable and willing to undergo a new mandatory post-treatment biopsy.
    • ChangedBefore 12 .Disease progression after at least 12 weeks of treatment with abiraterone for metastatic hormone-sensitive prostate cancer. Progression is defined as:Now 12 .Disease progression after at least 12 weeks of treatment with a prior androgen-receptor signalling inhibitor (ARPi), including abiraterone acetate or a direct AR inhibitor, such as enzalutamide, apalutamide, or darolutamide, for metastatic hormone-sensitive prostate cancer. Note: Patients who previously received Enzalutamide can be recruited but up to a maximum of 6. Those patients will be included directly into the experimental arm. Progression is defined as:
    • Editedand / or b. Limited radiographic progression: maximum of 2 new bone metastases, no new soft tissue metastasis and less than50percentincreasethan 50 percent increase in the size of measurable soft tissue lesions.
    • EditedReceived a maximum of 6 cycles of docetaxel for mHSPC. and b. Received the last dose of docetaxel equal or higher than 6 months prior to randomization.
    • Added14. Participants who have received prior Lu177-PSMA must meet the following criteria:
    • EditedReceived a maximum of 6 cycles of docetaxel for mHSPC. b. Received the last dose of Lu177-PSMA equal or higher than 6 months prior to randomization 15. Adequate organ function within 28 days before the first study treatment on Day 1, defined by the following:
    • EditedTotal serum bilirubin less than 1.5 × ULN (less than 3 × ULN for participants with documented Gilbert syndrome or for whom indirect bilirubin concentrations suggest an extrahepatic source of elevation). 16. Ability to swallow study medication tablets and comply with study requirements.
    • RemovedAbility to swallow study medication tablets and comply with study requirements.
    • Edited17. Agrees to use a condom and another effective method of birth control if he is having sex with a woman of childbearing potential or agrees to use a condom if he is having sex with a woman who is pregnant, starting contraception at screening and continue throughout the study period and for 3 months after the final treatment administration, (during the treatment period and for at least 90 days after last dose of enzalutamide or at least 120 days after las dose of talazoparib, whichever occurs later) unless the patient is unable to maintain intercourse due to the androgen deprivation.
    • ChangedBefore Subject agrees not to participate in another interventional study while on treatment.Now 19. Subject agrees not to participate in another interventional study while with experimental medical products or anticancer drugs not approved in this setting on treatment in this study. Exceptions could be allowed for protocols investigating the survival or quality of life impact of common routine or conventional drugs (i.e. acetylsalicylic acid, statins, oral antidiabetic drugs) as long as they do not intefere with the study treatment and the evaluation of the main study arms.
    Exclusion criteria
    • EditedPrior abirateroneARPi treatment for less than 12 weeks or disease progression (either PSA or radiographic progression) within 6 months of starting abiraterone or ARi.
    • RemovedDisease progression less than 6 months after the last administration of docetaxel for mHSPC.
    • RemovedA finding of superscan in a bone scan at screening. Superscan is defined as a bone scan which demonstrates markedly increased skeletal radioisotope uptake relative to soft tissues in association with absent or faint renal activity (absent kidney sign).
    • EditedUse of opiate analgesia for pain from prostate cancer with average Brief pain inventory (BPI) questionnaire score higher than or equal to 6 and/or uncontrolled prostate cancer-related pain requiring increasing doses of opiates within 4 weeks prior to randomization
    • RemovedPrior treatment with an AR-targeted therapy (enzalutamide, apalutamide, darolutamide, ketoconazole) other than abiraterone for mHSPC; chemotherapy other than 6 cycles of docetaxel for mHSPC, immunotherapy or radiopharmaceuticals.
    • AddedPrior treatment with more than one ARPi. This will include abiraterone, enzalutamide, apalutamide, or darolutamide, which are treatments with demonstrated PFS and/or OS benefit in mHPSC, as well as any other novel AR or androgen synthesis directed therapy (with the exception on LHRH/GnRH analogues and/or antagonists). Note: Patients who started on one ARPi and switched to another due to toxicity will only be eligible after prior discussion with the study chair, provided that they were on the first ARPi (other than enzalutamide) for a very limited period of time and can document that they were responding - without PSA rise or worsening symptoms - at the moment they were switched to the second ARPi. Inclusion of such cases will require written notification and approval from the study chair or co-chair.
    • EditedarticipantsParticipants with clinically significant cardiovascular disease including but not limited to any of the following:
    • EditedUncontrolled, persistent hypertension defined as systolic blood pressure lessgreater than 170mmHg or diastolic blood pressure lessgreater than100mmHg. Subjects with a history of hypertension are allowed provided blood pressure is controlled by anti-hypertensive treatment
    • EditedParticipants with any of the following cardiac conduction abnormalities: Ventricular arrhythmias except for benign premature ventricular contractions
    • AddedVentricular arrhythmias except for benign premature ventricular contractions
    Interventions Arm changed Enzalutamide and Talazoparib→Enzalutamide and Talazoparib. Post-AA/ARi according to prior treatment.
    Contact Study contact's phone or email changed: •••3615→•••8227. See the current contact
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Institut Català d'Oncologia (ICO) · Badalona, SpainContact person changed (no phone or email listed)
    • Hospital Universitario de Jerez de la Frontera · Cadiz, SpainContact removed (no phone or email listed)
    Title Talazoparib Plus Enzalutamide After Progression to AbirateronePrior ARPi in Metastatic Prostate Cancer: (TEAM PC)
    + 4 other changes: index terms, verification date, description and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06582628
Lead sponsor
Fundacion Oncosur
Responsible party
Sponsor
First posted
Sep 3, 2024
Start date
Jul 5, 2024
Primary completion
Dec 31, 2027 (estimated)
Completion
Feb 28, 2029 (estimated)
Last update
Oct 5, 2026

Study contacts

Luis Gonzaga Paz-Ares Rodríguez
Contact
info@oncosur.org
+34 91 560 82 27
Elena Castro, Dra.
Contact
ecastro.imas12@h12o.es
+34 91 560 82 27
Elena Castro, Dra.
principal investigator · Hospital 12 de Octubre
David Olmos, Dr.
study chair · Hospital 12 de Octubre

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Enzalutamide · Talazoparib

Start the discussion